Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften E-learning Web-tv Video Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Gepubliceerd in:
Inleiding: ‘Old age matters’ hoofdstuk lezen eerste hoofdstuk lezen

2022 | OriginalPaper | Hoofdstuk

10. Aandachtspunten bij farmacotherapie van de oudere patiënt

Auteur : Prof. dr. M. Petrovic

Gepubliceerd in: Geriatrie in de fysiotherapie en kinesitherapie

Uitgeverij: Bohn Stafleu van Loghum

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Samenvatting

Het aantal tachtigplussers neemt toe, wat resulteert in een toenemend aantal mensen met multimorbiditeit. Multimorbiditeit creëert polyfarmacie, wat bijgevolg, de meest consistente voorspeller is van ongepast voorschrijven en geneesmiddelgerelateerde problemen (GRP’s) bij ouderen. In dit hoofdstuk worden de belangrijkste kenmerken van polyfarmacie en de risico’s op GRP’s beschreven in relatie tot fysieke inspanningen. Vervolgens worden de stappen beschreven die moeten worden overwogen bij het voorschrijven voor ouderen en worden methoden voor het opsporen van GRP’s en optimalisatie van polyfarmacie uitgewerkt.
vorige hoofdstuk Pijn en palliatieve zorg
volgende hoofdstuk Vallen
Literatuur
1.
Gnjidic D, Hilmer S, Blyth F, Naganathan V, Waite L, Seibel M, McLachlan A, Cumming R, Handelsman J, Le Couteur D. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012;65:989–95.CrossRef
2.
Kantor E, Rehm C, Haas J, Chan A, Giovannucci E. Trends in prescription drug use among older adults in United States from 1992–2012. JAMA. 2015;314:1818–31.CrossRef
3.
Maust D, Gerlach L, Gibson A, Kales H, Blow F, Olfson M. Trends in central nervous system-active polypharmacy among older adults seen in outpatient care in the United States. JAMA Intern Med. 2017;177:583–5.CrossRef
4.
Gnjidic D, Hilmer S, Blyth F, Naganathan V, Cumming R, Handelsman D, McLachlan A, Abernethy D, Banks E, Le Couteur D. High risk prescribing and incidence of frailty among older community-dwelling men. Clin Pharmacol Ther. 2012;91:521–8.CrossRef
5.
Gallagher P, Lang P, Cherubini A, Topinková E, Cruz-Jentoft A, Montero-Errasquin B, Mádlová P, Gasperini B, Baeyens H, Baeyens J, Michel J, O’Mahony D. Prevalence of potentially inappropriate prescribing in an acutely ill population of older patients admitted to six European hospitals. Eur J Clin Pharmacol. 2011;67:1175–88.CrossRef
6.
Kouladjian L, Gnjidic D, Chen T, Mangoni A, Hilmer S. Drug burden index in older adults: theoretical and practical issues. Clin Interv Aging. 2014;9:1503–15.CrossRef
7.
Kashyap M, Belleville S, Mulsant B, Hilmer S, Paquette A, le Tu M, Tannenbaum C. Methodological challenges in determining longitudinal associations between anticholinergic drug use and incident cognitive decline. J Am Geriatr Soc. 2014;62:336–41.CrossRef
8.
Fried T, O’Leary J, Towle V, Goldstein M, Trentalange M, Martin D. Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review. J Am Geriatr Soc. 2014;62:2261–72.CrossRef
9.
Hilmer S, Gnjidic D. The effects of polypharmacy in older adults. Clin Pharmacol Ther. 2009;85:86–8.CrossRef
10.
Saum K, Schöttker B, Meid A, Holleczek B, Haefeli W, Hauer K, Brenner H. Is polypharmacy associated with frailty in older people? Results from the ESTHER cohort study. J Am Geriatr Soc. 2017;65:e27-32.CrossRef
11.
Jamsen K, Bell J, Hilmer S, Kirkpatrick C, Ilomäki J, Le Couteur D, Blyth F, Handelsman D, Waite L, Naganathan V, Cumming R, Gnjidic D. Effects of changes in number of medications and drug burden index exposure on transitions between frailty states and death: the concord health and ageing in men project cohort study. J Am Geriatr Soc. 2016;64:89–95.CrossRef
12.
Farmer C, Fenu E, O’Flynn N, Guthrie B. Clinical assessment and management of multimorbidity: summary of NICE guidance. BMJ. 2016;354:i4843.
13.
Clarke C, Withal M. The effects of medication on activity and rehabilitation of older people- opportunities and risks. Rehabilitation Process and Outcome. 2017;6:1–7.CrossRef
14.
Reeve E, Gnjidic D, Long J, Himer S. A systematic review of the emerging definition of ‘deprescribing’ with network analysis: implications for future research and clinical practice. Br J Clin Pharmacol. 2015;80:1254–68.CrossRef
15.
Patterson S, Cadogan C, Kerse N, Cardwell C, Bradley M, Ryan C, et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2014;CD008165.
16.
Hepler C, Strand L. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47:533–43.PubMed
17.
Gallagher P, Barry P, O’Mahony D. Inappropriate prescribing in the elderly. J Clin Pharm Ther. 2007;32:113–21.CrossRef
18.
Spinewine A, Schmader KE, Barber N, Hughes C, Lapane K, Swine C, Hanlon J. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet. 2007;370:173–84.CrossRef
19.
20.
Tommelein E, Mehuys E, Petrovic M, Somers A, Colin P, Boussery K. Potentially inappropriate prescribing in community-dwelling older people across Europe: a systematic literature review. Eur J Clin Pharmacol. 2015;71:1415–27.CrossRef
21.
Al Hamid A, Ghaleb M, Aljadhey H, Aslanpour Z. A systematic review of hospitalization resulting from medicine-related problems in adult patients. Br J Clin Pharmacol. 2014;78:202–17.CrossRef
22.
Nivya K, Sri Sai Kiran V, Ragoo N, Jayaprakash B, Sonal Sekhar M. Systemic review on drug related hospital admissions – A PubMed based search. Saudi Pharm J. 2015;23:1–8.
23.
Van den Bemt P, Egberts A, Lenderink A, Verzijl J, Simons K, Van der Pol W, Leufkens H. Risk factors for the development of adverse drug events in hospitalized patients. Pharm World Sci. 2000;22:62–6.CrossRef
24.
Hajjar E, Hanlon J, Artz M, Lindblad C, Pieper C, Sloane R, Ruby C, Schmader K. Adverse drug reaction risk factors in older outpatients. Am J Geriatr Pharmacother. 2003;1:82–9.CrossRef
25.
Field T, Gurwitz J, Avorn J, McCormick D, Jain S, Eckler M, et al. Risk factors for adverse drug events among nursing home residents. Arch Intern Med. 2001;161:1629–34.CrossRef
26.
Field T, Gurwitz J, Harrold L, Rothschild J, Debellis K, Seger A, et al. Risk factors for adverse drug events among older adults in the ambulatory setting. J Am Geriatr Soc. 2004;52:1349–54.CrossRef
27.
Lund B, Carnahan R, Egge J, Chrischilles E, Kaboli P. Inappropriate prescribing predicts adverse drug events in older adults. Ann Pharmacother. 2010;44:957–63.CrossRef
28.
Steinman M, Landefeld C, Rosenthal G, Berthenthal D, Sen S, Kaboli P. Polypharmacy and prescribing quality in older people. J Am Geriatr Soc. 2006;54:1516–23.CrossRef
29.
Page R, Linnebur S, Bryant L, Ruscin M. Inappropriate prescribing in the hospitalized elderly patient: defining the problem, evaluation tools, and possible solutions. Clin Interv Aging. 2010;5:75–87.CrossRef
30.
Klotz U, Avant G, Hoyumpa A, Schenker S, Wilkinson G. The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest. 1975;55:347–59.CrossRef
31.
Wang L. Epidemiology and prevention of adverse drug reactions in the elderly. J Geriatr Cardiol. 2005;2:248–53.
32.
Kinirons M, Crome P. Clinical pharmacokinetic considerations in the elderly. An update. Clin Pharmacokinet. 1997;33:302–12.CrossRef
33.
Kwan D, Farrell B. Polypharmacy: optimizing medication use in elderly patients. Can Geriatr J. 2014;4:21–7.
34.
Kolla BP, Lovely JK, Mansukhani MP, Morgenthaler TI. Zolpidem is independently associated with increased risk of inpatient falls. J Hosp Med. 2013;8(1–6):50.
35.
Nurminen J, Puustinen J, Lahteenmaki R, et al. Handgrip strength and balance in older adults following withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotics. BMC Geriatr. 2014;14:121.CrossRef
36.
Fox C, Smith T, Maidment I, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing. 2014;43:604–15.CrossRef
37.
Mintzer J, Burns A. Anticholinergic side-effects of drugs in elderly people. J R Soc Med. 2000;93:457–62.CrossRef
38.
Gnjidic D, Bell JS, Hilmer SN, Lönnroos E, Sulkava R, Hartikainen S. Drug burden index associated with function in community-dwelling older people in Finland: a cross-sectional study. Ann Med. 2012;44:458–67.CrossRef
39.
Salahudeen MS, Duffull SB, Nishtala PS. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatr. 2015;15:31.CrossRef
40.
Collamati A, Martone AM, Poscia A, et al. Anticholinergic drugs and negative outcomes in the older population: from biological plausibility to clinical evidence. Aging Clin Exp Res. 2016;28:25–35.CrossRef
41.
Rochon P, Gurwitz J. Optimising drug treatment for elderly people: the prescribing cascade. BMJ. 1997;315:1096–9.CrossRef
42.
43.
44.
Onder G, Van der Cammen TJ, Petrovic M, Somers A, Rajkumar C. Strategies to reduce the risk of iatrogenic illness in complex older adults. Age Ageing. 2013;42:284–91.CrossRef
Metagegevens
Titel
Aandachtspunten bij farmacotherapie van de oudere patiënt
Auteur
Prof. dr. M. Petrovic
Copyright
2022
Uitgeverij
Bohn Stafleu van Loghum
Boek
Geriatrie in de fysiotherapie en kinesitherapie

Print ISBN: 978-90-368-2782-9

Elektronisch ISBN: 978-90-368-2783-6

Copyright: 2022

DOI
https://doi.org/10.1007/978-90-368-2783-6_10